Welcome to our dedicated page for Know Labs SEC filings (Ticker: KNW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Researching Know Labs’ pathway to commercializing its Bio-RFID and ChromaID diagnostics often starts with one question: where in the SEC filings does the company discuss clinical milestones, FDA submissions, or cash runway? This page gathers every Know Labs filing—annual report 10-K, quarterly earnings report 10-Q, 8-K material events, proxy statements, and, crucially, insider trading Form 4 transactions—so you never hunt across EDGAR again.
Stock Titan’s AI engine reads each document the moment it hits EDGAR and produces plain-English highlights. Need the R&D expense trend from the last three quarters? Wonder how to read Know Labs’ 10-K without parsing 200 pages? Curious about “Know Labs insider trading Form 4 transactions” before a key regulatory update? Our AI answers these questions by spotlighting patent additions, executive stock awards, and any going-concern language—then links straight to the original text for audit trail peace of mind.
Use the filings the way professionals do:
- Track "Know Labs quarterly earnings report 10-Q filing" for burn-rate analysis
- Receive "Know Labs Form 4 insider transactions real-time" alerts to gauge management confidence
- Scan “Know Labs 8-K material events explained” for partnership or clinical-trial announcements
Whether you’re comparing quarter-over-quarter R&D, dissecting executive compensation in the proxy, or simply seeking “Know Labs SEC filings explained simply,” Stock Titan’s blend of comprehensive coverage and AI-powered summaries turns dense disclosures into actionable knowledge—so you can focus on understanding the company’s non-invasive diagnostics roadmap, not decoding legal prose.
USBC, Inc. filed a Form D reporting a completed exempt equity offering under Rule 506(b). The filing states a total offering amount of $119,868,025, with the entire amount sold and $0 remaining. The issuer is a Nevada corporation with principal office in Reno. The offering closed with one investor reported. Cohen & Company Securities, LLC received a closing fee equal to 1% of post-closing common stock: 3,909,549 shares at $0.335 per share totaling $1,309,699 (recorded as sales commissions). The issuer indicates no proceeds were paid to listed officers, directors or promoters.
Linda Jenkinson, a director of the issuer, was granted an option to purchase 4,760,000 shares of the issuer's common stock on 08/06/2025 under the 2021 Equity Incentive Plan. The option has an exercise price of $2.45 per share and an expiration date of 08/06/2035. The option vests 25% on the one-year anniversary of the grant date, with the remainder vesting in quarterly installments over the following three years. The Form 4 was signed on 08/15/2025.
Chapman Kirk, Chief Operating Officer and Director of USBC, Inc. (USBC), was granted an option on August 6, 2025 to purchase 7,140,000 shares of the company's common stock at an exercise price of $2.45 per share. The option vests 25% on the one-year anniversary of the grant and then in quarterly installments over the following three years, and is exercisable through August 6, 2035. The Form 4 was signed on August 15, 2025.
Know Labs, Inc. issued 357,815,000 shares of its common stock to Goldeneye 1995 LLC in a private placement under a Securities Purchase Agreement dated June 5, 2025, with the closing on August 6, 2025. Goldeneye paid $15,000,000 in cash and 1,000 Bitcoin for the shares at a per-share price of $0.335. The issuance results in Goldeneye and Robert Gregory Kidd each being the beneficial owner of 357,815,000 shares, representing approximately 93.1% of the class based on 384,234,130 shares reported outstanding.
Following the closing, the company appointed Robert Gregory Kidd as Chief Executive Officer, President and Chairman and named Linda Jenkinson as Vice Chair. The filing discloses Voting and Support Agreements under which certain stockholders holding approximately 37% of the voting power agreed to vote to approve the Purchase Agreement. The Reporting Persons state they currently have no other specific plans beyond those disclosed, while reserving the right to buy, sell or transfer shares in the future.
On August 6, 2025 Know Labs issued 357,815,000 shares of common stock to Goldeneye 1995 LLC in a private placement at $0.335 per share, disclosed on an initial Form 3. The filing names Robert Gregory Kidd as sole owner and manager of the reporting entity and states he has voting control and investment discretion over the shares.
Know Labs filed a Form 3 reporting that Robert Gregory Kidd disclosed beneficial ownership of 357,815,000 common shares held indirectly through Goldeneye 1995 LLC. The shares were issued in a private placement on 08/06/2025 at a purchase price of $0.335 per share. Kidd is identified as a Director, an Officer (CEO, President, Chairman) and a 10% owner, and he is the sole owner and manager of Goldeneye with voting control and investment discretion over the shares.
On August 6, 2025, Kitty B. Payne, an officer of Know Labs, Inc. (KNW), was granted an option to purchase 1,790,000 shares of the company's common stock at an exercise price of $2.45 per share under the 2021 Equity Incentive Plan. The option vests 25% on the one-year anniversary of the grant and then in quarterly installments over the following three years, tying vesting to continued service. The grant is reported as a direct ownership interest and the option shows an expiration date of August 6, 2035, indicating a 10-year term from the grant date. The Form 4 reports the transaction as an acquisition of derivative securities through the company plan.
FAQ
What is the current stock price of Know Labs (KNW)?
What is the market cap of Know Labs (KNW)?
